Cypherpunk Technologies Q2 2024 Earnings Report

Cypherpunk Technologies EPS Results

• Actual EPS: -$0.52
• Consensus EPS: -$0.42
• Beat/Miss: Missed by -$0.10
• One Year Ago EPS: N/A

Cypherpunk Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cypherpunk Technologies Announcement Details

• Quarter: Q2 2024
• Date: 8/12/2024
• Time: N/A
• Conference Call Date: Monday, August 12, 2024
• Conference Call Time: 7:00AM ET

Cypherpunk Technologies (NASDAQ:CYPH) Inc., previously known as Leap Therapeutics, Inc., is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Cypherpunk is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development.

Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and now trades on the NASDAQ under the ticker CYPH. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.